Back to News
Market Impact: 0.2
Vanda Pharmaceuticals Targets Major GLP-1 Market Challenge with Positive Trial Outcomes
Source: benzinga.com
Healthcare & Biotech
Vanda Pharmaceuticals released results from a Phase 3 trial of Nereus, an oral therapy intended to prevent vomiting associated with GLP-1 receptor agonist treatments. The article provides no trial outcomes or efficacy and safety figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Artiva halts AlloNK development, cuts 94% of workforce
- Universal Health Services falls 3% on legal settlement concerns
- Midterm elections: How affordability and the economy could impact voters
- Why is Artiva Biotherapeutics stock collapsing today?
- adar1 capital management buys $53,691 of NextCure stock
- Zura Bio shares jump on Wedbush buy call ahead of trial data